mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome
- PMID: 21189378
- PMCID: PMC4856022
- DOI: 10.1200/JCO.2010.32.7825
mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome
Conflict of interest statement
Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.
Figures
Similar articles
-
Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned.Oncologist. 2018 Apr;23(4):399-e33. doi: 10.1634/theoncologist.2017-0682. Epub 2018 Jan 25. Oncologist. 2018. PMID: 29371475 Free PMC article. Clinical Trial.
-
Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.Future Oncol. 2011 Sep;7(9):1025-9. doi: 10.2217/fon.11.88. Future Oncol. 2011. PMID: 21919689 No abstract available.
-
Promising advances in the treatment of malignant pancreatic endocrine tumors.N Engl J Med. 2011 Feb 10;364(6):564-5. doi: 10.1056/NEJMe1013903. N Engl J Med. 2011. PMID: 21306243 No abstract available.
-
Treatment: symptomatic treatment of hypoglycaemia.Ann Endocrinol (Paris). 2013 Jul;74(3):196-9. doi: 10.1016/j.ando.2013.05.009. Epub 2013 Jun 18. Ann Endocrinol (Paris). 2013. PMID: 23791453 No abstract available.
-
A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome.Fam Cancer. 2011 Sep;10(3):469-72. doi: 10.1007/s10689-011-9471-9. Fam Cancer. 2011. PMID: 21826537 Review.
Cited by
-
Molecular characteristics of pancreatic ductal adenocarcinoma.Patholog Res Int. 2011 Mar 27;2011:620601. doi: 10.4061/2011/620601. Patholog Res Int. 2011. PMID: 21512581 Free PMC article.
-
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.Gut. 2019 Apr;68(4):742-758. doi: 10.1136/gutjnl-2018-316822. Epub 2018 Nov 5. Gut. 2019. PMID: 30396902 Free PMC article. Review.
-
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23. Cancer Discov. 2017. PMID: 28336552 Free PMC article.
-
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.Nat Rev Clin Oncol. 2015 Jun;12(6):319-34. doi: 10.1038/nrclinonc.2015.53. Epub 2015 Mar 31. Nat Rev Clin Oncol. 2015. PMID: 25824606 Review.
-
New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer.Target Oncol. 2018 Dec;13(6):691-704. doi: 10.1007/s11523-018-0609-7. Target Oncol. 2018. PMID: 30470972 Review.
References
-
- Jenne DE, Reimann H, Nezu J, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998;18:38–43. - PubMed
-
- Hezel AF, Bardeesy N. LKB1: Linking cell structure and tumor suppression. Oncogene. 2008;27:6908–6919. - PubMed
-
- van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: A systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105:1258–1264. - PubMed
-
- Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119:1447–1453. - PubMed
-
- Hardie DG. AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8:774–785. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous